 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Psoriasis
This is a fluctuating but persistent skin disease that gets its name from the Greek word for "itch." The skin is inflamed, with red, thickened areas bearing silvery scales; it's seen most often on the elbows, knees, scalp, and lower back. It may be so mild that people don't know they have it. At the other end of the spectrum, severe psoriasis may cover large areas of the body.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Psoriasis Study CAIN457A2204
The purpose of this clinical research trial is to study the effectiveness of three dose levels of AIN457 in patients with chronic plaque-type psoriasis.
The drug AIN457 is considered investigational, which means that it is still being tested and is not approved by the FDA and is NOT available for sale in the U.S.
Trial phase: Phase 2a Participation Duration: Participants will be required to visit the study center approximately 16 times over a duration of 36 weeks. Protocol Number: CAIN457A2204 |
